Here, we summarize the key clinical studies of oral SERDs, ongoing clinical trials, and a glimpse of novel technologies to suppress ER function, aiming to provide an overview of the past, present, and future of oral SERDs and ER inhibitors in the treatment of breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.